Oric Pharmaceuticals
ORIC
78 hedge funds and large institutions have $639M invested in Oric Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 18 reducing their positions, and 13 closing their positions.
94% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 18
1.25% more ownership
Funds ownership: 97.24% → 98.49% (+1.3%)
5% less funds holding
Funds holding: 82 → 78 (-4)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
27% less capital invested
Capital invested by funds: $874M → $639M (-$235M)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.79M |
| 2 |
BlackRock
New York
|
+$7.89M |
| 3 |
AG
Artal Group
Luxembourg
|
+$6.57M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$4.36M |
| 5 |
Morgan Stanley
New York
|
+$2.92M |
Top Sellers
| 1 |
ABG
Ally Bridge Group
New York
|
-$10.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.49M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.16M |
| 4 |
Jennison Associates
New York
|
-$3.21M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.49M |
ORIC Hedge Fund Activity: Q2 2021 in Review
78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q2 2021, worth a combined $639M — down 27% from $874M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ORIC and 9 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 35 added.
The largest buyer was Eventide Asset Management, adding an estimated $9.79M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $10.1M sold.
- 78 institutional investors held Oric Pharmaceuticals (ORIC) as of Q2 2021, down from 82 in Q1 2021.
- Funds reported $639M of Oric Pharmaceuticals stock for Q2 2021, down 27% quarter-over-quarter.
- 9 funds opened new Oric Pharmaceuticals positions in Q2 2021 and 13 closed out, a net change of -4 holders.
- The largest Oric Pharmaceuticals buyer in Q2 2021 was Eventide Asset Management, an estimated $9.79M added.
- The largest Oric Pharmaceuticals seller in Q2 2021 was Ally Bridge Group, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2021.